To see the other types of publications on this topic, follow the link: World wide combined reporting.
Journal articles on the topic 'World wide combined reporting'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'World wide combined reporting.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Long, R., J. Luzuriaga, C. Biondi, A. Woods, P. Jackson, C. Anderiesz, C. Giles, and H. Zorbas. "Collection and Reporting of System-Wide Cancer Treatment Activity Data As Part of the Stage, Treatment and Recurrence (STaR) Project." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 74s. http://dx.doi.org/10.1200/jgo.18.61400.
Full textAbstract:
Background: The need for high quality, comprehensive national data on the treatments applied to cancers is widely recognized within the Australian cancer control community. The analysis and reporting of cancer treatment data will greatly enhance our ability to better understand cancer care activity and outcomes - and in particular the treatments being applied across population groups. Aim: To collect and report national data on cancer treatments, as part of Cancer Australia's Stage, Treatment and Recurrence (STaR) project. The linking of this data with national data on stage at diagnosis, survival and recurrence, will help inform policy and practice and ultimately improve cancer outcomes. Methods: Cancer Australia developed a dataset of selected surgical procedures for the treatment of the top five incidence cancers (prostate, breast, colorectal, lung, and melanoma). A dataset of key selected radiotherapy, and systemic therapies for the treatment of all cancer types was also developed. Data for reporting system-wide treatment activity were extracted from existing national health administrative datasets, including: the Pharmaceutical Benefits Scheme (PBS), the Medicare Benefits Schedule (MBS) and the National Hospital Morbidity Database (NHMD). The scope of the analysis was selected surgical procedures, radiotherapy procedures, or pharmaceutical agents administered with the general intent to change the outcome of the cancer and/or provide symptom relief/ palliative care. Results: The data reported provide a high-level national system-wide overview of cancer treatments applied, including: • More than 1 million radiotherapy services were provided for all cancers combined in Australia (as indicated by MBS reimbursement claims data) for the years 2013 to 2015 inclusive; • The number of people receiving systemic anticancer therapies in Australia for all cancers combined (as indicated by PBS reimbursement claims data) increased from 198,756 in 2012 to 247,939 in 2016; and • The number of hospital separations recorded in the NHMD (i.e., episodes of admitted patient care) for patients with a principal diagnosis of cancer undergoing surgery for the treatment of the top five high incidence cancers in Australia increased from 53,516 in 2010 to 57,651 in 2015. Conclusion: National cancer treatment data were successfully collected and reported. Australia is one of very few countries in the world to collect and report national system-wide treatment data with a specific focus on cancer. These data will be linked to cancer incidence, stage at diagnosis, survival and recurrence data to help inform for population-level reporting of cancer outcomes.
2
de Mouzon, Jacques, Georgina M. Chambers, Fernando Zegers-Hochschild, Ragaa Mansour, Osamu Ishihara, Manish Banker, Silke Dyer, Markus Kupka, and G. David Adamson. "International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology 2012†." Human Reproduction 35, no. 8 (July 23, 2020): 1900–1913. http://dx.doi.org/10.1093/humrep/deaa090.
Full textAbstract:
Abstract STUDY QUESTION What was the utilization, effectiveness and safety of practices in ART globally in 2012 and what global trends could be observed? SUMMARY ANSWER The total number of ART cycles increased by almost 20% since 2011 and the main trends were an increase in frozen embryo transfers (FET), oocyte donation, preimplantation genetic testing and single embryo transfers (SET), whereas pregnancy and delivery rates (PR, DR) remained stable, and multiple deliveries decreased. WHAT IS KNOWN ALREADY ART is widely practiced throughout the world, but continues to be characterized by significant disparities in utilization, availability, practice, effectiveness and safety. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) annual world report provides a major tool for tracking trends in ART treatment for over 25 years and gives important data to ART professionals, public health authorities, patients and the general public. STUDY DESIGN, SIZE, DURATION A retrospective, cross-sectional survey on the utilization, effectiveness and safety of ART procedures performed globally during 2012 was carried out. PARTICIPANTS/MATERIALS, SETTING, METHODS Sixty-nine countries and 2600 ART clinics submitted data on ART cycles performed during the year 2012, and their pregnancy outcome, through national and regional ART registries. ART cycles and outcomes are described at country, regional and global levels. Aggregate country data were processed and analyzed based on methods developed by ICMART. MAIN RESULTS AND ROLE OF CHANCE A total of 1 149 817 ART cycles were reported for the treatment year 2012. After imputing data for missing values and non-reporting clinics in reporting countries, 1 948 898 cycles (an increase of 18.6% from 2011) resulted in >465 286 babies (+17.9%) in reporting countries. China did not report and is not included in this estimate. The best estimate of global utilization including China is ∼2.8 million cycles and 0.9 million babies. From 2011 to 2012, the number of reported aspirations and FET cycles increased by 6.9% and 16.0%, respectively. The proportion of women aged 40 years or older undergoing non-donor ART increased from 24.0% in 2011 to 25.2% in 2012. ICSI, as a percentage of non-donor aspiration cycles, increased from 66.5% in 2011 to 68.9% in 2012. The IVF/ICSI combined delivery rates per fresh aspiration and FET cycles were 19.8% and 22.1%, respectively. In fresh non-donor cycles, SET increased from 31.4% in 2011 to 33.7% in 2012, while the average number of transferred embryos decreased from 1.91 to 1.88, respectively—but with wide country variation. The rates of twin deliveries following fresh non-donor transfers decreased from 19.6% in 2011 to 18.0% in 2012, and the triplet rate decreased from 0.9% to 0.8%. In FET non-donor cycles, SET was 54.8%, with an average of 1.54 embryos transferred and twin and triplet rates of 11.1% and 0.4%, respectively. The cumulative DR per aspiration increased from 28.0% in 2011 to 28.9% in 2012. The overall perinatal mortality rate per 1000 births was 21.4 following fresh IVF/ICSI and 15.9 per 1000 following FET. LIMITATIONS, REASONS FOR CAUTION The data presented depend on the quality and completeness of data submitted by individual countries to ICMART directly or through regional registries. This report covers approximately two-thirds of` world ART activity, with a major missing country, China. Continued efforts to improve the quality and consistency of reporting ART data by registries are still needed, including the use of internationally agreed standard definitions (International Glossary of Infertility and Fertility Care). WIDER IMPLICATIONS OF THE FINDINGS The ICMART world reports provide the most comprehensive global statistical census and review of ART utilization, effectiveness, safety and quality. While ART treatment continues to increase globally, the wide disparities in access to treatment, procedures performed and embryo transfer practices warrant attention by clinicians and policy makers. With the increasing practice of SET and of freeze all and resulting increased proportion of FET cycles, it is clear that PR and DR per aspiration in fresh cycles do not give an overall accurate estimation of ART efficiency. It is time to use cumulative live birth rate per aspiration, combining the outcomes of FET cycles with the associated fresh cycle from which the embryos were obtained, and to obtain global consensus on this approach. STUDY FUNDING/COMPETING INTEREST(S) The authors declare no conflict of interest and no specific support from any organizations in relation to this manuscript. ICMART gratefully acknowledges financial support from the following organizations: American Society for Reproductive Medicine; European Society for Human Reproduction and Embryology; Fertility Society of Australia; Japan Society for Reproductive Medicine; Japan Society of Fertilization and Implantation; Red Latinoamericana de Reproduccion Asistida; Society for Assisted Reproductive Technology; Ferring Pharmaceuticals and Abbott (both providing ICMART unrestricted grants unrelated to world reports). TRIAL REGISTRATION NUMBER NA.
3
Flores Baquero, Óscar, Alejandro Jiménez, and Agustí Pérez-Foguet. "Reporting progress on the human right to water and sanitation through JMP and GLAAS." Journal of Water, Sanitation and Hygiene for Development 5, no. 2 (February 11, 2015): 310–21. http://dx.doi.org/10.2166/washdev.2015.151.
Full textAbstract:
International institutions have the authority to monitor States' compliance with the Human Right to Water and Sanitation (HRWS) but the necessary tools for this task are not yet ready. The human development sector has a wider experience of using information about progress, which provides a perfect opportunity to develop this further. The World Health Organization (WHO)/United Nations Children's Fund (UNICEF) Joint Monitoring programme (JMP) and the UN Water Global Analysis and Assessment of Sanitation and Drinking-Water (GLAAS) data sets could be used for those with a mandate to monitor the right, contributing to this challenge. Consequently, the information they offer has been analysed through a human rights lens. A matrix has been constructed to specifically identify to what extent their data sets could be combined to monitor HRWS in a broad sense. The JMP-led post-2015 proposal makes a considerable contribution to outcome indicators for measuring right-holders’ enjoyment of the right, and GLAAS adds structural and process outcome indicators to measure duty-bearers’ conduct. However, there are still some critical gaps if both UN Water platforms are to be used to report progress on HRWS. Finally, the article suggests some ideas concerning the way these shortcomings could be addressed.
4
Kirkland, Teresa, and Geoffrey D. Taylor. "Urinary Tract Infections in Spinal Cord Injury Patients Undergoing Intermittent Catheterization Procedures." Canadian Journal of Infectious Diseases 3, no. 3 (1992): 129–33. http://dx.doi.org/10.1155/1992/409158.
Full textAbstract:
A prospective study was organized to assess whether feeding back infection rates to staff performing intermittent catheterization in spinal cord-injured patients would produce a fall in urinary tract infection rates. Over a 12 month period, infection rates for such procedures were reported to unit staff: reporting was combined with educational programs emphasizing aseptic catheterization techniques and the importance ofhandwashing. Overall infection rates for the 12 month period were 13.3 per 1000 days of intermittent catheterization - unchanged from the preceding six months (15.1 per 1000 days) by retrospective chart review. Likewise, there was no statistically significant downward trend during the prospective phase of the study. A wide variety of infecting organisms were found, of whichKlebsiellaspecies (39%),Escherichia coli(18%) andEnterobacterspecies (17%) were most common: most infections were asymptomatic. Patients with complete cord lesions at or above the sixth thoracic spinal cord segment (T6) had a much higher incidence of infection (73%) than those with incomplete lesions below T6 (33%).
5
Tooke, Emily W., and Benjamin Roe. "Extra-cranial Stereotactic Radiation Therapy (ESRT) in the treatment of inoperable stage 1 & 2 non-small-cell lung cancer patients with highly mobile tumours: a literature review." Journal of Radiotherapy in Practice 9, no. 4 (November 30, 2010): 247–59. http://dx.doi.org/10.1017/s1460396910000105.
Full textAbstract:
AbstractObjective: Extra-cranial Stereotactic Radiation Therapy (ESRT) techniques and equipment utilised in the treatment of Stage 1 or 2 inoperable non-small-cell lung cancer (NSCLC); accounting for Respiratory Induced Tumour Motion (RITM).Methods: A narrative review of current world literature.Results: Four main strategies are employed to address RITM: (1) tumour movement minimisation/immobilisation; (2) integration of respiratory movements into planning; (3) respiratory-gating techniques; and (iv) tumour-tracking techniques.Discussion: Analysis of data gathered suggests that due to inherent difficulties with respiratory function, combined with co-morbidities and the level of dose escalation facilitated by ESRT: techniques that do not require patient ability to comply are more likely to be effective with a wider range of patients. Similarly, treatment planning must incorporate accurate four-dimensional (4D) data to ensure target coverage, although setup and verification should be controlled to smaller margins for error.Conclusion: The disparate nature of reporting methods restricts statistical comparison. However, this paper suggests that the ESRT technique using abdominal compression (AC), free-breathing respiratory-gating (FBRG), 4D computed tomography (4DCT) planning, combined with daily on board kV cone beam computed tomography (CBCT) imaging for setup and target verification, is a possible candidate for further treatment regime assessments in large multi-centre trials.
6
Serena, Thomas E. "Incorporating Point-of-Care Bacterial Fluorescence into a Wound Clinic Antimicrobial Stewardship Program." Diagnostics 10, no. 12 (November 26, 2020): 1010. http://dx.doi.org/10.3390/diagnostics10121010.
Full textAbstract:
Background: In 2014 the World Health Organization (WHO) warned of an emerging world-wide crisis of antibiotic-resistant microorganisms. In response, government and professional organizations recommended that health care systems adopt antimicrobial stewardship programs (ASPs). In the United States, the Centers for Medicare Services (CMS) mandated antimicrobial stewardship in the hospital inpatient setting. Effective 1 January 2020, the Joint Commission required ambulatory centers that prescribe antibiotics, such as wound centers, to institute an ASP. Chronic wounds often remain open for months, during which time patients may receive multiple courses of antibiotics and numerous antimicrobial topical treatments. The wound clinician plays an integral role in reducing antimicrobial resistance in the outpatient setting: antibiotics prescribed for skin and soft tissue infections are among the most common in an outpatient setting. One of the most challenging aspects of antimicrobial stewardship in treating chronic wounds is the inaccuracy of bacterial and infection diagnosis. Methods: Joint Commission lists five elements of performance (EP): (1) identifying an antimicrobial stewardship leader; (2) establishing an annual antimicrobial stewardship goal; (3) implementing evidence-based practice guidelines related to the antimicrobial stewardship goal; (4) providing clinical staff with educational resources related to the antimicrobial stewardship goal; and (5) collecting, analyzing, and reporting data related to the antimicrobial stewardship goal. This article focuses on choosing and implementing an evidence-based ASP goal for 2020. Discussion: Clinical trials have demonstrated the ability of fluorescence imaging (MLiX) to detect clinically significant levels of bacteria in chronic wounds. Combined with clinical examination of signs and symptoms of infection, the MLiX procedure improves the clinician’s ability to diagnose infection and can guide antimicrobial use. In order to satisfy the elements of performance, the MLiX procedure was incorporated into the annual ASP goal for several wound care centers. Clinicians were educated on the fluorescence imaging device and guidelines were instituted. Collection of antimicrobial utilization data is underway.
7
Ismail, Hina M., Christopher G. Pretty, Matthew K. Signal, Marcus Haggers, and J. Geoffrey Chase. "Attributes, Performance, and Gaps in Current & Emerging Breast Cancer Screening Technologies." Current Medical Imaging Formerly Current Medical Imaging Reviews 15, no. 2 (January 10, 2019): 122–31. http://dx.doi.org/10.2174/1573405613666170825115032.
Full textAbstract:
Background:Early detection of breast cancer, combined with effective treatment, can reduce mortality. Millions of women are diagnosed with breast cancer and many die every year globally. Numerous early detection screening tests have been employed. A wide range of current breast cancer screening methods are reviewed based on a series of searchers focused on clinical testing and performance. </P><P> Discussion: The key factors evaluated centre around the trade-offs between accuracy (sensitivity and specificity), operator dependence of results, invasiveness, comfort, time required, and cost. All of these factors affect the quality of the screen, access/eligibility, and/or compliance to screening programs by eligible women. This survey article provides an overview of the working principles, benefits, limitations, performance, and cost of current breast cancer detection techniques. It is based on an extensive literature review focusing on published works reporting the main performance, cost, and comfort/compliance metrics considered.Conclusion:Due to limitations and drawbacks of existing breast cancer screening methods there is a need for better screening methods. Emerging, non-invasive methods offer promise to mitigate the issues particularly around comfort/pain and radiation dose, which would improve compliance and enable all ages to be screened regularly. However, these methods must still undergo significant validation testing to prove they can provide realistic screening alternatives to the current accepted standards.
8
Mastro, Dana, Anita Atwell Seate, Erin Blecha, and Monica Gallegos. "The Wide World of Sports Reporting." Journalism & Mass Communication Quarterly 89, no. 3 (May 21, 2012): 458–74. http://dx.doi.org/10.1177/1077699012447922.
Full text
9
Yao, Jane, Bo Green, and Monika K. Krzyzanowska. "Identifying potentially preventable emergency department (PPED) visits among patients with cancer in Ontario." Journal of Clinical Oncology 36, no. 30_suppl (October 20, 2018): 25. http://dx.doi.org/10.1200/jco.2018.36.30_suppl.25.
Full textAbstract:
25 Background: Cancer patients (pts) often visit the emergency department (ED) when symptoms and side effects occur. Growing evidence suggests that some treatment-related toxicities can be managed proactively in outpatient clinics, improving patient experience and optimizing acute care utilization. Understanding PPED visits is crucial to developing and evaluating such improvement efforts. Our objectives were to quantify the extent of PPED visits in Ontario among cancer pts and identify the best measure of PPED for province-wide quality improvement. Methods: By linking Activity Level Reporting to the Discharge Abstract Database and the National Ambulatory Care Reporting System, we identified cancer pts who had ED visits or hospitalizations up to 30 days after receiving chemotherapy and/or radiotherapy from April 1, 2014 to March 31, 2015 in Ontario. Episodes were stratified as ED Only or Indirect Admission (ED visit leading to hospitalization). We mapped the presenting Canadian Emergency Department Information System (CEDIS) complaints against the PPED metric proposed by Panattoni et al (JOP, 2018) that combined the CMS preventable visits typology with the STAR PRO tool (Basch et al, JCO, 2016) which found 49.8% were considered potentially preventable (PP). Results: We identified 43,593 ED visits (67% ED Only& 33% Indirect Admissions) among 64,407 pts. The most common presenting CEDIS complaints were pain (20%), fever (13%) and shortness of breath (SoB, 7%) among chemotherapy pts, and pain (19%), SoB (11%) and general weakness (9%) among radiotherapy pts. By applying the CEDIS-based PPED definition, which includes 17 presenting complaints, 50% of ED Only and 68% of Indirect Admission visits were considered PPED. Conclusions: We were able to adapt the PPED algorithm for the Canadian context, which can aid cross-jurisdiction comparisons. We found a substantial proportion of PPED visits. While common presenting complaints had face validity for being PP and a similar proportion of visits were PP compared to the US-based definition, further validation of this approach against healthcare records and in other jurisdictions would be helpful as these metrics become increasingly used for quality improvement.
10
Motaze, Nkengafac Villyen, Zinhle E. Mthombothi, Olatunji Adetokunboh, C. Marijn Hazelbag, Enrique M. Saldarriaga, Lawrence Mbuagbaw, and Charles Shey Wiysonge. "The Impact of Rubella Vaccine Introduction on Rubella Infection and Congenital Rubella Syndrome: A Systematic Review of Mathematical Modelling Studies." Vaccines 9, no. 2 (January 25, 2021): 84. http://dx.doi.org/10.3390/vaccines9020084.
Full textAbstract:
Introduction: Rubella vaccines have been used to prevent rubella and congenital rubella syndrome (CRS) in several World Health Organization (WHO) regions. Mathematical modelling studies have simulated introduction of rubella-containing vaccines (RCVs), and their results have been used to inform rubella introduction strategies in several countries. This systematic review aimed to synthesize the evidence from mathematical models regarding the impact of introducing RCVs. Methods: We registered the review in the international prospective register of systematic reviews (PROSPERO) with registration number CRD42020192638. Systematic review methods for classical epidemiological studies and reporting guidelines were followed as far as possible. A comprehensive search strategy was used to identify published and unpublished studies with no language restrictions. We included deterministic and stochastic models that simulated RCV introduction into the public sector vaccination schedule, with a time horizon of at least five years. Models focused only on estimating epidemiological parameters were excluded. Outcomes of interest were time to rubella and CRS elimination, trends in incidence of rubella and CRS, number of vaccinated individuals per CRS case averted, and cost-effectiveness of vaccine introduction strategies. The methodological quality of included studies was assessed using a modified risk of bias tool, and a qualitative narrative was provided, given that data synthesis was not feasible. Results: Seven studies were included from a total of 1393 records retrieved. The methodological quality was scored high for six studies and very high for one study. Quantitative data synthesis was not possible, because only one study reported point estimates and uncertainty intervals for the outcomes. All seven included studies presented trends in rubella incidence, six studies reported trends in CRS incidence, two studies reported the number vaccinated individuals per CRS case averted, and two studies reported an economic evaluation measure. Time to CRS elimination and time to rubella elimination were not reported by any of the included studies. Reported trends in CRS incidence showed elimination within five years of RCV introduction with scenarios involving mass vaccination of older children in addition to routine infant vaccination. CRS incidence was higher with RCV introduction than without RCV when public vaccine coverage was lower than 50% or only private sector vaccination was implemented. Although vaccination of children at a given age achieved slower declines in CRS incidence compared to mass campaigns targeting a wide age range, this approach resulted in the lowest number of vaccinated individuals per CRS case averted. Conclusion and recommendations: We were unable to conduct data synthesis of included studies due to discrepancies in outcome reporting. However, qualitative assessment of results of individual studies suggests that vaccination of infants should be combined with vaccination of older children to achieve rapid elimination of CRS. Better outcomes are obtained when rubella vaccination is introduced into public vaccination schedules at coverage figures of 80%, as recommended by WHO, or higher. Guidelines for reporting of outcomes in mathematical modelling studies and the conduct of systematic reviews of mathematical modelling studies are required.
11
Podlasek, Anna, Permesh Singh Dhillon, Waleed Butt, Iris Q. Grunwald, and Timothy J. England. "Direct mechanical thrombectomy without intravenous thrombolysis versus bridging therapy for acute ischemic stroke: A meta-analysis of randomized controlled trials." International Journal of Stroke 16, no. 6 (June 2, 2021): 621–31. http://dx.doi.org/10.1177/17474930211021353.
Full textAbstract:
Background Direct mechanical thrombectomy may result in similar outcomes compared to a bridging approach with intravenous thrombolysis (IVT + MT) in acute ischemic stroke. Recent randomized controlled trials have varied in their design and noninferiority margin. Aim We sought to meta-analyze accumulated trial data to assess the difference and non-inferiority in clinical and procedural outcomes between direct mechanical thrombectomy and bridging therapy. Summary of review We conducted a systematic review of electronic databases following the preferred reporting items for systematic reviews and meta-analyses guidelines. Random effects meta-analyses were conducted for the pooled data. The primary outcome was good functional outcome at 90 days (modified Rankin scale (mRS) ≤ 2). Secondary outcomes included excellent functional outcome (mRS ≤ 1), mortality, any intracranial hemorrhage, symptomatic intracranial hemorrhage, successful reperfusion (thrombolysis in cerebral infarction ≥ 2 b), and procedure-related complications. Four randomized controlled trials comprising 1633 patients (817 direct mechanical thrombectomy, 816 bridging therapy) were included. There were no statistical differences for the 90-day good functional outcome (OR = 1.02, 95% CI 0.84–1.25, p = 0.54, I2 = 0%), and the absolute risk difference was 1% (95% CI: −4% to 5%). The lower 95% CI falls within the strictest noninferiority margin of −10% among included randomized control trials. Direct mechanical thrombectomy reduced the odds of successful reperfusion (OR = 0.76, 95% CI: 0.60–0.97, p = 0.03, I2 = 0%) and any intracranial hemorrhage (OR = 0.65, 95% CI: 0.49–0.86, p = 0.003, I2 = 38%). There was no difference in the remaining secondary outcomes. The risk of bias for all studies was low. Conclusion The combined trial data assessing direct mechanical thrombectomy versus bridging therapy showed no difference in improving good functional outcome. The wide noninferiority thresholds set by individual trials are in contrast with the clinical consensus on minimally important differences. However, our pooled analysis indicates noninferiority of direct mechanical thrombectomy with a 4% margin of confidence. The application of these findings is limited to patients presenting directly to mechanical thrombectomy-capable centers and real-world workflow times may differ against those achieved in a trial setting.
12
Sardella, Marco, and Calin Lungu. "Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives." Therapeutic Advances in Drug Safety 10 (January 2019): 204209861988281. http://dx.doi.org/10.1177/2042098619882819.
Full textAbstract:
Different strategies have been studied to allow a better characterization of the safety profile of orphan drugs soon after their approval. At the end of the development phases only few data are available because of the small number of subjects exposed to an orphan medicine for the treatment of rare or ultra-rare conditions. As a consequence, the evaluation of the safety profile is limited at the time of the first approval. In the post-marketing period, all available sources should be combined for a better understanding of the safety of orphan drugs. These sources, include outputs from large databases such as the European Medicines Agency’s EudraVigilance database. Analyses of data from this source are required to be performed by marketing authorization holders (MAHs) as part of their signal management activities. In 2018, the Pharmacovigilance Risk Assessment Committee (PRAC) assessed 114 confirmed signals, 79% of which included data from EudraVigilance. MAHs have access to statistical calculations for drug–event combinations (DECs) from EudraVigilance, provided in the form of measures of disproportionality of ratios of the observed proportion of spontaneous cases for a DEC in relation to the proportion of cases that would be expected if no association existed between the drug and the event. However, such statistical summaries for orphan drugs could be misleading because of the very limited safety data available for orphan drugs (under-reporting together with low numbers of exposed patients). In addition, the applied statistical methodology in most instances is constrained by different confounding factors such as indications of specific medicines and the wide spectrum of medical conditions/diseases of patients from whom reporting of disproportionality ratios are derived (i.e. proportions of DECs for orphan drugs (ODECs) from a small patient population suffering the rare disease and the proportion of DECs in the rest of the population represented in the whole database who have been treated with other medicines for a wide range of indications, and prescribed to treat completely different medical conditions). As expected, these statistical calculations produced not only signals of disproportionate reporting (SDRs) that are false positives, but also not sensitive enough to detect certain SDRs, thus resulting in false negatives. In the context of rare/ultra-rare life-threatening diseases where new molecules have been made available on the market on the basis of their proven efficacy, but with only limited safety data at the time of approval, false negatives could be a special concern since unlikely converted in positives or becoming positives with notable delay. Subgroup analyses (using a limited dataset comprising ADRs within specific individual case safety reports (ICSRs), sorted by indication/disease relevant to the drug of interest could, at least in part, possibly reduce some of the weaknesses resulting from the abovementioned confounding factors. On the other hand it could also cause the loss of some identification of SDRs that would be captured if no database restrictions had been undertaken. Therefore, data subgroup analysis should not be selected as a preferred approach to quantitative signal detection for orphan drugs but rather evaluated as complementary possibly to confirm negatives or to further characterize detected SDRs. Some examples of false negatives originating from quantitative signal detection in EudraVigilance applied to orphan drugs are discussed in this article.
13
Williams, Iestyn, Daisy Phillips, Charles Nicholson, and Heather Shearer. "Evaluation of a deliberative approach to citizen involvement in health care priority setting." Leadership in Health Services 27, no. 1 (January 28, 2014): 5–19. http://dx.doi.org/10.1108/lhs-01-2013-0002.
Full textAbstract:
Purpose – The purpose of this paper is to describe and evaluate a novel approach to citizen engagement in health priority setting carried out in the context of Primary Care Trust (PCT) commissioning in the English National Health Service. Design/methodology/approach – Four deliberative events were held with 139 citizens taking part in total. Events design incorporated elements of the Twenty-first Century Town Meeting and the World Café, and involved specially-designed dice games. Evaluation surveys reporting quantitative and qualitative participant responses were combined with follow-up interviews with both PCT staff and members of the public. An evaluation framework based on previous literature was employed. Findings – The evaluation demonstrates high levels of enjoyment, learning and deliberative engagement. However, concerns were expressed over the leading nature of the voting questions and, in a small minority of responses, the simplified scenarios used in dice games. The engagement exercises also appeared to have minimal impact on subsequent Primary Care Trust resource allocation, confirming a wider concern about the influence of public participation on policy decision making. The public engagement activities had considerable educative and political benefits and overall the evaluation indicates that the specific deliberative tools developed for the exercise facilitated a high level of discussion. Originality/value – This paper helps to fill the gap in empirical evaluations of deliberative approaches to citizen involvement in health care priority setting. It reports on a novel approach and considers a range of implications for future research and practice. The study raises important questions over the role of public engagement in driving priority setting decision making.
14
Frey, Christopher, Peter Chia Yeh, and Prathap Jayaram. "Effects of Antiplatelet and Nonsteroidal Anti-inflammatory Medications on Platelet-Rich Plasma: A Systematic Review." Orthopaedic Journal of Sports Medicine 8, no. 4 (April 1, 2020): 232596712091284. http://dx.doi.org/10.1177/2325967120912841.
Full textAbstract:
Background: Platelet-rich plasma (PRP) has wide applications in orthopaedic care. Its beneficial effects are attributed to the growth factor profile from the platelet secretome. In theory, these effects would be diminished by medications that inhibit platelet activation and/or the subsequent release of growth factors. Purpose: To determine whether commonly used antiplatelets, nonsteroidal anti-inflammatory drugs (NSAIDs), or anticoagulant medications affect platelet growth factor release in PRP. Study Design: Systematic review; Level of evidence, 2. Method: A systematic review of the literature related to antiplatelet, anti-inflammatory, and anticoagulant drugs was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We used the Downs and Black objective quality scoring system. The literature search consisted of PubMed and Cochrane Library databases. Search terms consisted of 1 item selected from “platelet-rich plasma,” “platelet-derived growth factor,” and “platelet-rich plasma AND growth factor” combined with 1 item from “antiplatelet,” “aspirin,” “anticoagulant,” and “NSAID.” Only studies published within the past 25 years were included. Results: A total of 15 studies met the inclusion criteria: 7 studies detected no significant decrease in growth factors or mitogenesis, whereas 6 detected a decrease with antiplatelet agents, 1 detected mixed results with an antiplatelet agent, and 1 had mixed results with an antiplatelet agent/vasodilator. In terms of PRP activation, all 3 studies assessing collagen, the 2 studies analyzing adenosine diphosphate alone, and the 1 study investigating arachidonic acid found a decrease in growth factor concentration. Conclusion: Antiplatelet medications may decrease the growth factor release profile in a cyclooxygenase 1– and cyclooxygenase 2–dependent manner. Eight of 15 studies found a decrease in growth factors or mitogenesis. However, more studies are needed to comprehensively understand antiplatelet effects on the PRP secretome.
15
Pearson, Lauren N., Jill M. Miller, John H. Lunde, Ronald J. Bryant, Michael R. Lewis, and Mary E. Tang. "Combined Pathology-Driven Algorithmic Testing and Integrated Reporting for Bone Marrow Examination." Archives of Pathology & Laboratory Medicine 143, no. 6 (January 23, 2019): 732–37. http://dx.doi.org/10.5858/arpa.2018-0161-oa.
Full textAbstract:
Context.— The College of American Pathologists published guideline recommending bone marrow synoptic reporting for hematologic neoplasms. Objective.— To evaluate the impact of pathology-driven algorithmic testing (PDAT) with integrated reporting for bone marrow examination on test utilization, ability to render a specific World Health Organization diagnosis, and clinician satisfaction 1 year after implementation. Design.— We reviewed the hematopathology reports, integrated synoptic reports, and ancillary test results generated during a 12-month period. The initial diagnosis from the hematopathology report was compared with the final diagnosis on the integrated synoptic reports. Test utilization data were compared with a previous year in which ancillary testing was ordered at clinician discretion. Clinicians were anonymously surveyed to assess their satisfaction with PDAT and integrated reporting. Results.— Integrated reporting resulted in a World Health Organization diagnosis for 80 of 85 cases (94%) compared with 54 (64%) for the hematopathology report alone. Unnecessary testing decreased from 45% pre-PDAT (124 of 274 cases) to 0.7% PDAT (2 of 268 cases), and PDAT resulted in fewer omissions of necessary tests. Clinicians preferred PDAT and valued integrated reporting for a variety of reasons, including the ease of finding relevant prognostic information. Conclusions.— Pathology-driven algorithmic testing with integrated reporting improves the pathologist's ability to render a specific World Health Organization diagnosis and improves test utilization. Clinicians prefer PDAT to clinician-ordered testing. This is the first study to examine how synoptic reporting can modify hematologic diagnoses.
16
Soh, Dominic S. B. "Sustainability Reporting and Assurance: A Historical Analysis on a World-Wide Phenomenon." Social and Environmental Accountability Journal 34, no. 2 (May 4, 2014): 125. http://dx.doi.org/10.1080/0969160x.2014.938484.
Full text
17
Boston, A. N., and D. R. B. Stockwell. "Interactive species distribution reporting, mapping and modelling using the World Wide Web." Computer Networks and ISDN Systems 28, no. 1-2 (December 1995): 231–38. http://dx.doi.org/10.1016/0169-7552(95)00113-9.
Full text
18
Junior, Renzo Mori, Peter J. Best, and Julie Cotter. "Sustainability Reporting and Assurance: A Historical Analysis on a World-Wide Phenomenon." Journal of Business Ethics 120, no. 1 (February 8, 2013): 1–11. http://dx.doi.org/10.1007/s10551-013-1637-y.
Full text
19
Brouwer, Lieke, Giulia Moreni, Katja C. Wolthers, and Dasja Pajkrt. "World-Wide Prevalence and Genotype Distribution of Enteroviruses." Viruses 13, no. 3 (March 8, 2021): 434. http://dx.doi.org/10.3390/v13030434.
Full textAbstract:
Enteroviruses (EVs) are highly prevalent viruses world-wide, causing a wide range of diseases in both children and adults. Insight in the global prevalence of EVs is important to define their clinical significance and total disease burden, and assists in making therapeutic decisions. While many studies have been conducted to describe epidemiology of EVs in specific (sub)populations and patient cohorts, little effort has been made to aggregate the available evidence. In the current study, we conducted a search in the PubMed and Embase (Ovid) databases to identify articles reporting EV prevalence and type distribution. We summarized the findings of 153 included studies. We found that EVs are highly prevalent viruses in all continents. Enterovirus B was the most detected species worldwide, while the other species showed continent-specific differences, with Enterovirus C more detected in Africa and Enterovirus A more detected in Asia. Echovirus 30 was by far the most detected type, especially in studies conducted in Europe. EV types in species Enterovirus B—including echovirus 30—were often detected in patient groups with neurological infections and in cerebrospinal fluid, while Enterovirus C types were often found in stool samples.
20
Ulma, William, and David M. Schlabach. "Technical Considerations in Remote LIMS Access via the World Wide Web." Journal of Automated Methods and Management in Chemistry 2005, no. 4 (2005): 217–22. http://dx.doi.org/10.1155/jammc.2005.217.
Full textAbstract:
The increased dependency on the World Wide Web by both laboratories and their customers has led LIMS developers to take advantage of thin-client web applications that provide both remote data entry and manipulation, along with remote reporting functionality. Use of an LIMS through a web browser allows a person to interact with a distant application, providing both remote administration and real-time analytical result delivery from virtually anywhere in the world. While there are many benefits of web-based LIMS applications, some concern must be given to these new methods of system architecture before justifying them as a suitable replacement for their traditional client-server systems. Developers and consumers alike must consider the security aspects of introducing a wide area network capable system into a production environment, as well as the concerns of data integrity and usability.
21
Baltatzis, M., H. V. Spiers, S. Jegatheeswaran, and A. Siriwardena. "World-wide variation in reporting of the longitudinal pancreatojejunostomy with partial pancreatic head resection (Frey Procedure)." HPB 23 (2021): S213—S214. http://dx.doi.org/10.1016/j.hpb.2020.11.535.
Full text
22
Jansson, Andreas. "Global financial reporting convergence: A study of the adoption of International Financial Reporting Standards by the Swedish accountancy profession." Competition & Change 24, no. 5 (October 29, 2018): 429–49. http://dx.doi.org/10.1177/1024529418808970.
Full textAbstract:
International Financial Reporting Standards (IFRS) is a financial reporting standard for listed corporations in more than half of the world’s countries. This wide adoption combined with its influence on accounting in countries that have not formally adopted it makes IFRS a remarkable case of far-reaching convergence. This paper develops a framework that integrates institutional theory and political economy and employs a discourse analytical approach to address the issue of why the Swedish accountancy profession came to accept and adopt IFRS. The analysis covers the professional debates regarding the measurement of the value of assets and liabilities in the main professional journal over the nearly two decades in which IFRS was gradually integrated into the local accounting standards on a voluntary basis prior to its formal adoption. The analysis emphasizes the combination of a pervasive international development discourse that stresses the significance of financial markets developing into a sense of inevitability and an elite portion of the accountancy profession with a vested interest in change. IFRS can be seen as a strategic professionalization project for the elite members of the accountancy profession which, combined with financial interests, led to its endorsement of the changes and alignment with forces of financialization.
23
Louis, David N., Pieter Wesseling, Sebastian Brandner, Daniel J. Brat, David W. Ellison, Felice Giangaspero, Eyas M. Hattab, et al. "Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting." Archives of Pathology & Laboratory Medicine 144, no. 2 (June 20, 2019): 196–206. http://dx.doi.org/10.5858/arpa.2018-0565-oa.
Full textAbstract:
Context.— Standards for pathology reporting of cancer are foundational to national and international benchmarking, epidemiology, and clinical trials, with international standards for pathology reporting of cancer being undertaken through the International Collaboration on Cancer Reporting (ICCR). Objective.— To develop standardized templates for brain tumor diagnostic pathology reporting. Design.— As a response to the 2016 updated 4th edition of the WHO (World Health Organization) Classification of Tumours of the Central Nervous System (2016 CNS WHO), an expert ICCR committee developed data sets to facilitate reporting of brain tumors that are classified histologically and molecularly by the 2016 CNS WHO; as such, this represents the first combined histologic and molecular ICCR data set, and required a novel approach with 3 highly related data sets that should be used in an integrated manner. Results.— The current article and accompanying ICCR Web site describe reporting data sets for central nervous system tumors in the hope that they provide easy-to-use and highly reproducible means to issue diagnostic reports in consort with the 2016 CNS WHO. Conclusions.— The consistent use of these templates will undoubtedly prove useful for patient care, clinical trials, epidemiologic studies, and monitoring of neuro-oncologic care around the world.
24
Liu, Lu-Jie, Xiang-Xiang Li, Hui Wang, Bo Xue, Xiao-Ming Zheng, and Min Chen. "Application of combined plasma-catalytic method for carbon particulate matter (PM) removal." RSC Advances 5, no. 50 (2015): 40012–17. http://dx.doi.org/10.1039/c4ra13662d.
Full text
25
Bulyga, R. P., and I. V. Safonova. "XBRL as a Digital Reporting Format for Economic Entities: International Experience and Russian Practice Abstract." Accounting. Analysis. Auditing 7, no. 3 (July 7, 2020): 6–17. http://dx.doi.org/10.26794/2408-9303-2020-7-3-6-17.
Full textAbstract:
The issue of global transformation of the traditional format of accounting (financial) and non-financial reporting (in the form of PDF reports) into an interactive digital format of business reporting is relevant. The article is devoted to the analysis of domestic and world trends in the development of reporting of economic entities in the digital economy and identifying the prospects for using XBRL as the main digital format of business reporting. The research methodology is based on the application of a system of scientific methods: analysis and synthesis, induction and deduction, comparison, a systematic and logical approach and the method of analogies and groupings. As a result of the study, the trend in the development of reporting by economic entities is determined. The study justifies the strengthening of the role of information technology in the formation of new conceptual approaches to the disclosure of the information contained in it by synthesizing the elements of volumetric representation (using the method of “multidimensional space”) and modern IT platforms. A review of the use of the XBRL format as a world language for business reporting in international and Russian practice is conducted. Based on the analysis of global XBRL development initiatives actively discussed in the world community, it is concluded that the XBRL format has firmly taken the place of the main digital standard for the formation and disclosure of information by economic entities of leading world countries, and its further development is an inevitable future in solving the problem of creating a modern interactive digital format of business reporting of foreign and domestic companies. The research results can be used by a wide range of national regulators, investors and financial market participants, as well as international business and professional communities, with the practical transfer of all financial market participants to a single electronic format.
26
Chung, Hyeesoo (Sally), Sudha Krishnan, John Lauck, and Jinyoung Wynn. "Market reactions to the internal control reporting presentation format: combined vs separate audit reports." Managerial Auditing Journal 36, no. 7 (August 17, 2021): 979–98. http://dx.doi.org/10.1108/maj-12-2020-2951.
Full textAbstract:
PurposeThis paper aims to investigate whether the stock market reacts to presentation options available to auditors under AS 2 (providing separate financial statement audit and internal control over financial reporting [ICOFR] audit reports, or presenting a combined report with both audit opinions). Design/methodology/approachDrawing on psychology theory, the authors hypothesize that presenting material weaknesses in ICOFR with an unqualified financial statement audit in a combined report effectively dilutes the weight placed on the material weaknesses perceived by investors. The authors further hypothesize the presentation format effect to vary by type of material weaknesses since some material weaknesses are considered more serious than others. The authors examine ICOFR and audit reporting and cumulative abnormal return data from 2007 to 2017 using two-stage least squares regression analysis. FindingsThe results show that a combined report of ineffective ICOFR and unqualified financial statement audit reduces the negative impact of material weakness disclosures on stock price reactions, but only when the weaknesses involve more serious entity-wide controls, as opposed to controls over specific accounts. Practical implicationsThe findings help inform preparers, auditors, regulators and investors about the potentially unintended consequences of reporting format choice. Originality/valueThe findings contribute to the literature on internal control disclosures by demonstrating that market reactions to these disclosures depend not only on the types of material weaknesses disclosed but also on their presentation format.
27
Cotterill, Sarah, Peter John, and Marie Johnston. "How can better monitoring, reporting and evaluation standards advance behavioural public policy?" Policy & Politics 49, no. 1 (January 1, 2021): 161–79. http://dx.doi.org/10.1332/030557320x15955052119363.
Full textAbstract:
Behavioural public policy interventions have been implemented across the world, targeting citizens, professionals, politicians and policymakers. This article examines poor quality reporting of interventions and methods in some behavioural public policy research. We undertake a review of existing reporting standards to assess their suitability for the behavioural public policy context. Our findings reveal that the adoption of standards can improve the reliability and reproducibility of research; provide a more robust evidence base from which to generalise findings; and convince sceptics of the value of behavioural public policy research. We conclude that use of the Template for Intervention Description and Replication (TIDieR) checklist and the Behaviour Change Technique Taxonomy (BCTTv1) would add rigour to intervention reporting. We argue there is a need for a combined tool to guide the design and reporting of randomised controlled trials, incorporating elements from the Consolidated Standards of Reporting Trials (CONSORT) checklist and other sources.
28
Lawrence, Heidi Y., Rachael G. Lussos, and Jessica A. Clark. "Rhetorics of Proposal Writing: Lessons for Pedagogy in Research and Real-World Practice." Journal of Technical Writing and Communication 49, no. 1 (December 13, 2017): 33–50. http://dx.doi.org/10.1177/0047281617743016.
Full textAbstract:
Proposals are ubiquitous documents with challenges beyond the writing task itself, such as project management, strategic development, and research. Reporting on proposal instruction research in other fields and the results of an interview study with proposal writers, this article argues for a shift in how proposals are taught and conceptualized. By coaching students on the wide range of rhetorical practices that proposals require rather than how to produce proposal documents, technical and professional communication instruction can better prepare future communicators to manage and produce competitive proposals and more actively participate in these important efforts in the community, industry, and academy.
29
Masum, Mahmud Al, and Lee D. Parker. "Local implementation of global accounting reform: evidence from a developing country." Qualitative Research in Accounting & Management 17, no. 3 (March 6, 2020): 373–404. http://dx.doi.org/10.1108/qram-10-2018-0073.
Full textAbstract:
Purpose While the world-wide adoption of international financial reporting standards (IFRS) aims to eliminate differences in national accounting standards between countries, the socio-political institutions surrounding financial reporting practices remain localised. This paper aims to penetrate and reveal the manner in which local national context, stakeholder intentions and financial reporting practices can moderate the compliance with IFRS in a developing country. Design/methodology/approach An interview-based qualitative research framework was used to analyse the experience and attitudes of accountants, auditors and financial reporting regulators during a passage of accounting reform initiatives. Findings This paper provides a critical analysis of the financial reporting practices of a developing country that has ostensibly implemented accounting reforms prescribed by the World Bank. It has revealed the key firm- and field-level logics that are experienced and managed by regulators and corporate managers in their approaches to financial reporting and accountability. The World Bank-led accounting reform can be constrained by a complex mix of institutional logics originating from market and corporate structures, networks of institutionalised family and political relationships, professional and regulatory structure and resourcing limitations and cultural business conventions. This paper provides evidence of firm- and field-level logics that contest and influence the emergence of a financial reporting oversight body and lead to highly variable compliance with international accounting standards. Originality/value This paper aims to extend our knowledge beyond broad national-level elements of institutional orders. It presents a more penetrating examination of the existence and contestation of logics originating from various local and global actors and interests. It presents a theoretical mapping of institutional logics, which operate in international and local settings and also encompass firm- and field-level imperatives. Any effort to understand and improve accounting practices of a developing country need to consider the power, contestation and influence of multiple logics operating in its institutional environment.
30
Helsby, Matthew A., Joe R. Fenn, and Andrew D. Chalmers. "Reporting research antibody use: how to increase experimental reproducibility." F1000Research 2 (July 10, 2013): 153. http://dx.doi.org/10.12688/f1000research.2-153.v1.
Full textAbstract:
Research antibodies are used in a wide range of bioscience disciplines, yet it is common to hear dissatisfaction amongst researchers with respect to their quality. Although blame is often attributed to the manufacturers, scientists are not doing all they can to help themselves. One example of this is in the reporting of research antibody use. Publications routinely lack key details, including the host species, code number and even the company who supplied the antibody. Authors also fail to demonstrate that validation of the antibodies has taken place. These omissions make it harder for reviewers to establish the likely reliability of the results and for researchers to reproduce the experiments. The scale of this problem, combined with high profile concerns about experimental reproducibility, has caused the Nature Publishing Group to include a section on antibody information in their recent Reporting Checklist for Life Science Articles. In this commentary we consider the issue of reporting research antibody use and ask what details authors should be including in their publications to improve experimental reproducibility.
31
Helsby, Matthew A., Joe R. Fenn, and Andrew D. Chalmers. "Reporting research antibody use: how to increase experimental reproducibility." F1000Research 2 (August 23, 2013): 153. http://dx.doi.org/10.12688/f1000research.2-153.v2.
Full textAbstract:
Research antibodies are used in a wide range of bioscience disciplines, yet it is common to hear dissatisfaction amongst researchers with respect to their quality. Although blame is often attributed to the manufacturers, scientists are not doing all they can to help themselves. One example of this is in the reporting of research antibody use. Publications routinely lack key details, including the host species, code number and even the company who supplied the antibody. Authors also fail to demonstrate that validation of the antibodies has taken place. These omissions make it harder for reviewers to establish the likely reliability of the results and for researchers to reproduce the experiments. The scale of this problem, combined with high profile concerns about experimental reproducibility, has caused the Nature Publishing Group to include a section on antibody information in their recent Reporting Checklist for Life Science Articles. In this commentary we consider the issue of reporting research antibody use and ask what details authors should be including in their publications to improve experimental reproducibility.
32
Asmussen Andreasen, R., L. E. Kristensen, X. Baraliakos, V. Strand, P. J. Mease, M. De Wit, T. Ellingsen, et al. "THU0614-HPR ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 548.2–550. http://dx.doi.org/10.1136/annrheumdis-2020-eular.809.
Full textAbstract:
Background:The Assessment of SpondyloArthritis international Society (ASAS) has defined separate core sets for: i) symptom-modifying anti-rheumatic drugs (SM-ARD), ii) clinical record keeping, and iii) disease-controlling anti-rheumatic therapy (DC-ART). These all include the following domains: ‘physical function’, ‘pain’, ‘spinal mobility’, ‘spinal stiffness’ and ‘patient global assessment’ (PGA). The core set for clinical record keeping further includes the domains ‘peripheral joints’ and ‘acute phase reactants’, and the core set for DC-ART further includes the domains ‘fatigue’, ‘spine/hip radiographs’.Objectives:To assess the effect of interventions for each of the 9 axSpA core domains.Methods:We investigated the efficacy across all interventions included in Cochrane reviews according to the core outcome set for axSpA, as reported in these eligible axSpA trials. We combined data using the standardized mean difference (SMD) to meta-analyze outcomes involving similar constructs. By meta-regression analysis, we examined the effect for each of the nine separate SMD measures on the primary endpoint across all trials.Results:Among 85 articles screened, we included 43 trials with 63 randomized comparisons. Mean (SD) number of core outcomes domains measured for SM-ARD trials was 4.2 (1.7). 6 trials assessed all 5 proposed domains. Mean (SD) for number of core outcome domains for DC-ART trials was 5.8 (1.7). Unfortunately, no trials assessed all 9 domains. 8 trials were judged to have high risk of selective outcome reporting. The most responsible core domains for achieving success in meeting the primary objective per trial were pain; OR (95% CI) 5.19 (2.28, 11.77) and PGA; OR (95% CI) 1.87 (1.14, 3.07).Conclusion:Overall outcome reporting was good for SM-ARD trials, and poor for DC-ART trials. None of the DC-ART trials assessed all 9 domains. Outcome-reporting bias and ‘missing data’ should be reduced by implementing the endorsed ASAS/OMERACT outcome domains in all clinical trials. Our findings suggest that PGA and pain likely provide a holistic assessment of disease beyond “objective measures” of spinal inflammation.Disclosure of Interests:Rikke Asmussen Andreasen: None declared, Lars Erik Kristensen Consultant of: UCB Pharma (Advisory Board), Sannofi (Advisory Board), Abbvie (Advisory Board), Biogen (Advisory Board), Speakers bureau: AbbVie, Amgen, Biogen, Bristol-Myers Squibb,Celgene, Eli Lilly, Gilead, Forward Pharma, Janssen Pharmaceuticals, MSD, Novartis, Pfizer, and UCB Pharma, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Vibeke Strand Consultant of: AbbVie, Amgen, Biogen, Celltrion, Consortium of Rheumatology Researchers of North America, Crescendo Bioscience, Eli Lilly, Genentech/Roche, GlaxoSmithKline, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, UCB, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Maarten de Wit Grant/research support from: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Consultant of: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Speakers bureau: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Torkell Ellingsen: None declared, Inger Marie Jensen Hansen: None declared, Jamie Kirkham: None declared, George Wells: None declared, Peter Tugwell: None declared, Lara Maxwell: None declared, Maarten Boers: None declared, Kenneth Egstrup: None declared, Robin Christensen Grant/research support from: Dr. Christensen reports non-financial support from Board membership, grants from Consultancy (AbbVie, Amgen, Axellus A/S, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Eli Lilly, Hospira, MSD, Norpharma, Novartis, Orkla Health, Pfizer, Roche, Sobi, Takeda), personal fees from Employment (Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark), non-financial support from Expert testimony, grants from Grants/grants pending (Axellus A/S, AbbVie, Cambridge Weight Plan, Janssen, MSD, Mundipharma, Novartis, and Roche), grants from Payment for lectures including service on speakers bureaus (Abbott, Amgen, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Janssen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, Sobi, and Wyeth), grants from Payment for manuscript preparation (Axellus, Bristol-Myers Squibb, and Cambridge Weight Plan, Aleris-Hamlet (via Norpharma)), non-financial support from Patents (planned, pending or issued), non-financial support from Royalties, grants from Payment for development of educational presentations (Bristol-Myers Squibb, MSD, Pfizer), non-financial support from Stock/stock options, grants from Travel/accommodations/meeting expenses unrelated to activities listed (Abbott, AbbVie, Axellus, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Laboratoires Expanscience, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, and Wyeth), non-financial support from Other (err on the side of full disclosure), outside the submitted work; and I am involved in many health-care initiatives and research that could benefit from wide uptake of this publication (including Cochrane, OMERACT, IDEOM, RADS, and the GRADE Working Group).Musculoskeletal Statistics Unit, The Parker Institute is grateful for the financial support received from public and private foundations, companies and private individuals over the years. The Parker Institute is supported by a core grant from the Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its establishment in 1983, has given grants to not-for-profit organizations around the world.., Consultant of: Dr. Christensen reports non-financial support from Board membership, grants from Consultancy (AbbVie, Amgen, Axellus A/S, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Eli Lilly, Hospira, MSD, Norpharma, Novartis, Orkla Health, Pfizer, Roche, Sobi, Takeda), personal fees from Employment (Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark), non-financial support from Expert testimony, grants from Grants/grants pending (Axellus A/S, AbbVie, Cambridge Weight Plan, Janssen, MSD, Mundipharma, Novartis, and Roche), grants from Payment for lectures including service on speakers bureaus (Abbott, Amgen, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Janssen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, Sobi, and Wyeth), grants from Payment for manuscript preparation (Axellus, Bristol-Myers Squibb, and Cambridge Weight Plan, Aleris-Hamlet (via Norpharma)), non-financial support from Patents (planned, pending or issued), non-financial support from Royalties, grants from Payment for development of educational presentations (Bristol-Myers Squibb, MSD, Pfizer), non-financial support from Stock/stock options, grants from Travel/accommodations/meeting expenses unrelated to activities listed (Abbott, AbbVie, Axellus, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Laboratoires Expanscience, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, and Wyeth), non-financial support from Other (err on the side of full disclosure), outside the submitted work; and I am involved in many health-care initiatives and research that could benefit from wide uptake of this publication (including Cochrane, OMERACT, IDEOM, RADS, and the GRADE Working Group).Musculoskeletal Statistics Unit, The Parker Institute is grateful for the financial support received from public and private foundations, companies and private individuals over the years. The Parker Institute is supported by a core grant from the Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its establishment in 1983, has given grants to not-for-profit organizations around the world.., Speakers bureau: Dr. Christensen reports non-financial support from Board membership, grants from Consultancy (AbbVie, Amgen, Axellus A/S, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Eli Lilly, Hospira, MSD, Norpharma, Novartis, Orkla Health, Pfizer, Roche, Sobi, Takeda), personal fees from Employment (Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark), non-financial support from Expert testimony, grants from Grants/grants pending (Axellus A/S, AbbVie, Cambridge Weight Plan, Janssen, MSD, Mundipharma, Novartis, and Roche), grants from Payment for lectures including service on speakers bureaus (Abbott, Amgen, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Janssen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, Sobi, and Wyeth), grants from Payment for manuscript preparation (Axellus, Bristol-Myers Squibb, and Cambridge Weight Plan, Aleris-Hamlet (via Norpharma)), non-financial support from Patents (planned, pending or issued), non-financial support from Royalties, grants from Payment for development of educational presentations (Bristol-Myers Squibb, MSD, Pfizer), non-financial support from Stock/stock options, grants from Travel/accommodations/meeting expenses unrelated to activities listed (Abbott, AbbVie, Axellus, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Laboratoires Expanscience, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, and Wyeth), non-financial support from Other (err on the side of full disclosure), outside the submitted work; and I am involved in many health-care initiatives and research that could benefit from wide uptake of this publication (including Cochrane, OMERACT, IDEOM, RADS, and the GRADE Working Group).Musculoskeletal Statistics Unit, The Parker Institute is grateful for the financial support received from public and private foundations, companies and private individuals over the years. The Parker Institute is supported by a core grant from the Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its establishment in 1983, has given grants to not-for-profit organizations around the world.
33
Gratwohl, Alois, Helen Baldomero, Mahmoud Aljurf, Marcelo C. Pasquini, Luis Fernando Bouzas, Ayami Yoshimi, Jeffrey Szer, et al. "Hematopoietic Stem Cell Transplantation: a Global Perspective From the Worldwide Network of Blood and Marrow Transplantation." Blood 114, no. 22 (November 20, 2009): 809. http://dx.doi.org/10.1182/blood.v114.22.809.809.
Full textAbstract:
Abstract Abstract 809 Hematopoietic stem cell transplantation (HSCT) has become the standard of care for many patients with defined congenital or acquired disorders of the hematopoietic system. It has seen rapid expansion over the last two decades. HSCT is frequently considered as high cost and highly specialized medicine restricted to countries with abundant resources. This view needs to be changed; HSCT might represent the most cost effective therapy in certain situations. In an attempt to obtain a global overview, the WBMT, has collected information from 1,350 transplant centers in 71 reporting countries over all continents on the numbers of HSCT by indication and donor type for 2006. Data were analyzed by four regions, based on the WHO classification (www.who.org): America (North, Central and South America), Asia (South East Asia and Western Pacific, including Australia and New Zealand), Europe and EMRO/Africa (Eastern Mediterranean region and Africa). Main indications were compared within and between regions. Transplant rates (number of HSCT per 10 million inhabitants) were computed and compared with several macro-economic health care indicators by single and multiple linear regression analyzes. They included gross national income per capita (GNI/capita), total health care expenditures, governmental health care expenditures, adult, infant and maternal mortality rate, hospital beds, cesarean section rates and human developmental index (http://hdr.undp.org). There were a total of 51,421 first HSCT, 22,163 allogeneic (43%), 29,258 autologous (57%). Main indications were leukemias 17,553 (34%; 89% allogeneic), lymphomas 27,778 (54%; 87% autologous), solid tumors 2,954 (6%; 95% autologous) and non-malignant disorders 2,771 (5%; 93% allogeneic). There were significant differences between and within regions: autologous HSCT was the preferred type of HSCT in America (58%) and Europe (61%), allogeneic HSCT in Asia (57%) and in EMRO Africa (65%). The proportion of unrelated donors was highest in Asia (49%); it was negligible in EMRO/Africa (6%). Leukemia was the main indication for allogeneic HSCT globally (71%). Non-malignant/congenital diseases represented about 10% of all HSCT globally; with almost 40% activity reported in EMRO/Africa. A minimum income as measured by GNI per capita and a minimum size as measured by its population or size were the primary prerequisites for performing HSCT in an individual country. No transplants were performed in countries with less than 300 000 inhabitants, less than 960 km2 of size and less than 680 US$ GNI per capita. All macro-economic factors has a significant positive or negative (mortality ratios) association with transplant rates (p<0.05; t-test) but with variable explanatory content: Governmental Health Care Expenditures (r2= 77.33), Gross National Income per Capita (r2= 74.04), team density (r2= 76.28) and, Human Developmental Index (r2= 74.36) explained best transplant rates. Weak explanations were found with, adult (r2= 49.03), infant (r2= 66.31) and maternal mortality rate (r2= 63.21), hospital beds (r2= 32.04) or, caesarean section rates (r2= 30.56). If all factors are combined in regression analyzes explanatory content reaches r2 = 84.24 but the significance of human development index is lost due to multicolinearity. In conclusion, this first global overview on HSCT activity demonstrates that HSCT is an accepted therapy world-wide today, with different needs and priorities in different countries. Transplant activity is concentrated in countries with higher health care expenditures, highest GNI/capita and high team density; hence, governmental support, access to a transplant center, disease prevalence and availability of resources are the key factors related to regional transplant activity. These data provide a solid basis for up-to-date health care counseling and targeted interventions and support the establishment of comprehensive regional registries. Disclosures: Gratwohl: AMGEN: Research Funding; Bristo Myers Squibb: Research Funding; Roche: Research Funding; Novartis: Research Funding; Pfizer: Research Funding.
34
Jairath, Vipul, Myriam Martel, Richard FA Logan, and Alan N. Barkun. "Why Do Mortality Rates for Nonvariceal Upper Gastrointestinal Bleeding Differ around the World? A Systematic Review of Cohort Studies." Canadian Journal of Gastroenterology 26, no. 8 (2012): 537–43. http://dx.doi.org/10.1155/2012/862905.
Full textAbstract:
BACKGROUND: Discrepancies exist in reported mortality rates of nonvariceal upper gastrointestinal bleeding (NVUGIB).OBJECTIVE: To perform a systematic review assessing possible reasons for these disparate findings and to more reliably compare them.METHODS: The MEDLINE, EMBASE and ISI Web of Knowledge databases were searched for studies reporting mortality rates in NVUGIB involving adults and published in English. To ensure robust and contemporary estimates, studies spanning 1996 to January 2011 that included more than 1000 patients were selected.RESULTS: Eighteen of 3077 studies were selected. Ten studies used administrative databases and the remaining eight used registries. The mortality rates reported in these studies ranged from 1.1% in Japan to 11% in Denmark. There were variations in reported mortality rates among countries and also within countries. Reasons for these disparities included a spectrum of quality in reporting as well as heterogeneous definitions of case ascertainment, differing patient populations with regard to severity of presentation and associated comorbidities, varying durations of follow-up and different health care system-related practices.CONCLUSIONS: Wide differences in reported NVUGIB mortality rates are attributable to differences in adopted methodologies and populations studied. More uniform standards in reporting are needed; only then can true observed variations enable a better understanding of causes of death and pave the way to improved patient outcomes.
35
Ivanova, Galina, Ark Andreev, and Marwa A. Shouman. "Multi-agent System for Documents Retrieval and Evaluation Using Fuzzy Inference Systems." IAES International Journal of Artificial Intelligence (IJ-AI) 5, no. 4 (December 1, 2015): 158. http://dx.doi.org/10.11591/ijai.v5.i4.pp158-164.
Full textAbstract:
Recently the World Wide Web are packed with huge quantities of information. From this view the user finds it difficult to get the relevant informations due to the increased of their quantities. This paper uses multi-agent system uses intelligent agent in order to retrieval documents from the World Wide Web. The user by this system can easily get the relevant documents which to need them.Multi-agent System is combined with fuzzy inference system for ranking documents. The documents ranking score by cosine similarity using fuzzy inference system development and implemented much simpler than the traditional method which require mathematical equations.
36
Emberson, Robert, Dalia Kirschbaum, and Thomas Stanley. "New global characterisation of landslide exposure." Natural Hazards and Earth System Sciences 20, no. 12 (December 14, 2020): 3413–24. http://dx.doi.org/10.5194/nhess-20-3413-2020.
Full textAbstract:
Abstract. Landslides triggered by intense rainfall are hazards that impact people and infrastructure across the world, but comprehensively quantifying exposure to these hazards remains challenging. Unlike earthquakes or flooding, which cover large areas, landslides occur only in highly susceptible parts of a landscape affected by intense rainfall, which may not intersect human settlement or infrastructure. Existing datasets of landslides around the world generally include only those reported to have caused impacts, leading to significant biases toward areas with higher reporting capacity, limiting our understanding of exposure to landslides in developing countries. In this study, we use an alternative approach to estimate exposure to landslides in a homogenous fashion. We have combined a global landslide hazard proxy derived from satellite data with open-source datasets on population, roads and infrastructure to consistently estimate exposure to rapid landslide hazards around the globe. These exposure models compare favourably with existing datasets of rainfall-triggered landslide fatalities, while filling in major gaps in inventory-based estimates in parts of the world with lower reporting capacity. Our findings provide a global estimate of exposure to landslides from 2001 to 2019 that we suggest may be useful to disaster mitigation professionals.
37
Lin, John C., Allison J. Chen, Ingrid U. Scott, and Paul B. Greenberg. "U.S. News & World Report Ophthalmology Hospital Rankings and Research Productivity." Journal of Academic Ophthalmology 13, no. 01 (January 2021): e46-e50. http://dx.doi.org/10.1055/s-0040-1722743.
Full textAbstract:
Abstract Introduction Despite the wide usage of U.S. News & World Report (U.S. News) rankings of ophthalmology hospitals among the public, residency applicants, and ophthalmologists, there is disagreement in the literature on the role of quality of care, research productivity, and other factors in the ranking system. This study investigated the association of U.S. News ranking of ophthalmology hospitals and objective measures of research productivity. Methods The 2020 U.S. News “Best Hospitals for Ophthalmology” ranking lists 38 hospitals by reputation score and numerically ranks the top 12 institutions. For our analysis, top 12 hospitals were classified as group A and the remaining 26 as group B. The Clinicaltrials.gov, National Institutes of Health (NIH) Research Portfolio Online Reporting Tools Expenditures and Results (RePORTER), and NIH Research Portfolio Online Reporting Tools (RePORT) were systematically searched for total clinical trials, NIH funding, and the National Eye Institute (NEI) funding for fiscal years 2017, 2018, and 2019. Faculty size and the number of publications by ophthalmology faculty per hospital were recorded from a previous study in 2016. Results Independent measures of research productivity significantly associated with group A status after multivariate logistic regression analysis were mean faculty Hirsch's index (h-index) over 15 (odds ratio [OR]: 6.13, 95% confidence interval [CI]: [1.14–32.94]) and conducting five or more total clinical trials (OR: 8.77, 95% CI: [1.39–55.16]). Conclusion This study suggests that the reputation-based U.S. News ranking may serve as a proxy for an ophthalmology department's contribution to research measured by mean faculty h-index and number of clinical trials.
38
N P, Rajiv, Aruna D R, Avinash J L, Rekha Jagadish, and Anvi Gupta. "A novel approach to retrieve fractured mini implants." Journal of Dental Panacea 3, no. 2 (August 15, 2021): 78–81. http://dx.doi.org/10.18231/j.jdp.2021.017.
Full textAbstract:
Mini implant screws are accepted world wide as it provides a stable anchorage for the various types of orthodontic tooth movements. Use of mini screw implant includes risks such as screw fracture and screw failure. With the increased use of mini implants in dentistry, there is increase in cases of mini implant fracture. Reporting and management of fractured mini implant has not been given adequate importance. We are presenting a case of successful management of fractured mini implant using ultrasonic vibrations.
39
Cheng, Xian, Liao Stephen Shaoyi, and Zhongsheng Hua. "Measuring the systemic importance of interconnected industries in the world economic system." Industrial Management & Data Systems 117, no. 1 (February 6, 2017): 110–30. http://dx.doi.org/10.1108/imds-10-2015-0442.
Full textAbstract:
Purpose The purpose of this paper is to measure the systemic importance of industry in the world economic system under the system-wide event – the crisis of 2008-2009, by viewing this system as a weighted directed network of interconnected industries. Design/methodology/approach First, the authors investigate this crisis at three different levels based on network-related indicators: the “macro” global level, the “meso” country level, and the “micro” industry level. This investigation not only provides evidence for the systemic influence, that is, systemic risk, of the crisis, but also reveals the contagion mechanism of the crisis, which supports the stress testing. Second, the authors use a network-related business intelligence algorithm, the combined hyperlink-induced topic search (HITS) algorithm, to measure the contribution of a given individual industry to the overall risk of the economic system or, in other words, the systemic importance of the individual industry. Findings The HITS algorithm considers both the market information and the interconnectedness of the industries. Based on the stress testing, the performance of the combined HITS is compared with the purely market-based systemic risk measurement. The results show that the combined HITS outperforms the baseline in finding the top N systemically important industries. Practical implications The combined HITS algorithm provides a novel network-based perspective of systemic risk measurement. Originality/value Measuring the systemic importance based on the combined HITS algorithm can help managers and regulators design effective risk management policies. In this respect, the work initiates a research direction of studying the systemic risk in a business system based on a network-related business intelligence algorithm because the business system can be viewed as an interconnected network.
40
Hesse, Amélie Carolina, Daniel Behme, André Kemmling, Antonia Zapf, Nils Große Hokamp, Isabelle Frischmuth, Ilko Maier, et al. "Comparing different thrombectomy techniques in five large-volume centers: a ‘real world’ observational study." Journal of NeuroInterventional Surgery 10, no. 6 (September 28, 2017): 525–29. http://dx.doi.org/10.1136/neurintsurg-2017-013394.
Full textAbstract:
Background and purposeThrombectomy has become the standard of care for acute ischaemic stroke due to large vessel occlusion. Aim of this study was to compare the radiological outcomes and time metrics of the various thrombectomy techniques.MethodsIn this retrospective, multicenter study we analysed the data of 450 patients with occlusion of the anterior circulation, treated in five high-volume center from 2013 to 2016. The treatment techniques were divided in three categories: first-pass use of a large-bore aspiration-catheter; first-pass use of a stent-retriever; and primary combined approach (PCA) of an aspiration-catheter and stent-retriever. Primary endpoints were successful reperfusion and groin to reperfusion time. Secondary endpoints were the number of attempts and occurrence of emboli in new territory (ENT). The primary analysis was based on the intention to treat groups (ITT).ResultsThe ITT-analysis showed significantly higher reperfusion rates, with 86% of successful reperfusion in the PCA-group compared with 73% in the aspiration group and 65% in the stent-retriever group. There was no significant difference in groin to reperfusion time regarding the used technique. The secondary analysis showed an impact of the technique on the number of attempts and the occurrence of ENTs. Lowest ENT rates and attempts were reported with the combined approach.ConclusionsThe combined first-pass deployment of a stent-retriever and an aspiration-catheter was the most effective technique for reperfusion of anterior circulation large vessel occlusion. Our results correlate with the latest single-centrere studies, reporting very high reperfusion rates with PCA variations.
41
Oreshkova, Hristina. "THE FUTURE OF CORPORATE REPORTING REFLECTIONS ON THE CRITICAL QUESTION OF THE NECESSITY OF FORWARD-THINKING PHILOSOPHY AND CULTURE OF REPORTING WORLDWIDE." Knowledge International Journal 28, no. 5 (December 10, 2018): 1455–66. http://dx.doi.org/10.35120/kij28051455h.
Full textAbstract:
Over the most recent decades corporate reporting has proved to be essential to achieving the strategic goals of humankinds and the ever-increasing necessity of truthful information and transparency. Corporate reporting is a socially significant process and practice. The quality of corporate reporting reflects the degree of relevance of the manner enterprises and businesses communicate with the surrounding world and environment (natural or industrial) and millions of people concerned – societies, present and future generations, employees, workers, and many other people, and other living beings. On most authoritative international scientific forums – symposia, conferences, congresses, assemblies, summit meetings and events, conducted in Europe and worldwide, it is pompously declared that corporate reporting should provide useful and reliable information both financial and non-financial one. The responsibilities of accountability and stewardship seem out to be of great importance to the fulfillment of the strategic goals of our centuries.The belief of the author is that the simultaneous analysis of the global problems challenging humankinds such as climate changes, destruction of biological diversity on the Planet, the matter of the necessity of actions of creating Green Ethics and Green Economy worldwide, the increasing need for combined and well-coordinated efforts in the combat supporting the eradication of poverty globally, and the relevance of corporate reporting to solving these unique problems the mankind is facing, would highlight and confirm their intricate interrelation (the key aim of the present research), consequently rendering the debate on the future of corporate reporting more meaningful and constructive. The debate would most probably promote the standpoint we personally maintain, which is also endorsed by an increasing number of supporters in Europe and around the world, implying in particular that apart from a process of unification and reduction of essential differences in the international financial reporting, what is also necessary is the radical change in the philosophy and culture of corporate reporting and presentation. Undeniably, it includes revealing of the financial state and the substantial effects and impacts of the businesses operating activities in a straightforward manner, as complete insights and understanding of the broader and far-reaching goals to which the corporate reporting must be subordinated – at present and in the long-lasting future.
42
Massey, Andrew, Sarah Lindsay, Dexter Seow, Jonny Gordon, and David J. Lowe. "Bubble concept for sporting tournaments during the COVID-19 pandemic: Football Club World Cup." BMJ Open Sport & Exercise Medicine 7, no. 2 (June 2021): e001126. http://dx.doi.org/10.1136/bmjsem-2021-001126.
Full textAbstract:
ObjectivesTo report the person-to-staff transmission of COVID-19 with the implementation of a bubble concept that included testing, hygiene, distancing and monitoring strategies to mitigate risks.MethodsA prospective case series included all staff on-site involved in the Football Club World Cup. The tournament was conducted within ‘bubbles’. All personnel travelling to the tournament were required to be in possession of a negative RT-PCR test within 72 hours of arrival and subjected to a testing schedule during the tournament. Each location was assigned a COVID-19 protocol enforcement officer to ensure adherence to regular testing, hygiene measures, physical distancing and daily symptom reporting (via ScribePro app).ResultsThe study involved 70 recruited staff with a combined 1321 test days on the symptom checker app. The mean number of days completed on the symptom checker app was 18.87 days (range: 7–28). Of the five questions asked as part of the daily symptom checker, only one was answered positively (0.015%). This individual was isolated, assessed within 20 min and tested. The initial diagnosis was likely a non-COVID-19-related viral illness. Further testing returned three negative tests during the remainder of the tournament.ConclusionsThere was no person-to-staff transmission of COVID-19 during the tournament within our sample. The organisation of a sporting tournament during the COVID-19 pandemic is possible with risk mitigation strategies. These strategies include setting up a bubble with regular testing, hygiene measures, physical distancing and daily symptom reporting.
43
Sakurai, Kunie, and Wataru Fujibuchi. "Developing Global Cellular Information Retrieval System with Minimum Reporting Guidelines on Cellular Data for Regenerative Medicine." Genomics and Computational Biology 3, no. 2 (January 31, 2017): 50. http://dx.doi.org/10.18547/gcb.2017.vol3.iss2.e50.
Full textAbstract:
A wide range of stem cell research towards regenerative medicine has been conducted in a large number of domains in the world over the years. However, those produced data and information are not fully utilized and sometimes causes failure to be reproduced among laboratories or cell banks due to a lack of standardization of cellular assay reporting formats. To maximize a value placed on the information in stem cell and derivative cell research, we have proposed reporting guidelines for describing cellular assay data to pursue the facilitation of practical regenerative medicine named ‘Minimum Information About a Cellular Assay for Regenerative Medicine (MIACARM)’. MIACARM has been developed based on the existing Minimum Information About a Cellular Assay (MIACA) with defined taxonomy of human cell types, which allows for the description of advanced cellular experiments. MIACARM is applicable for exchanging data from not only for basic cellular assay, but also stem cell assay data that are produced and provided by cell banks, registries, or other academic institutions all over the world. And here we would like to introduce our recent progress that is developing stem cell data retrieval system based on MIACARM.
44
Peifer, R. W. "Integrating Digital Multimedia, Computer-based Instruction, and the World Wide Web into an Introductory Biology Curriculum." HortScience 31, no. 4 (August 1996): 697b—697. http://dx.doi.org/10.21273/hortsci.31.4.697b.
Full textAbstract:
During the past 6 years, the General Biology Program at the Univ. of Minnesota has been exploring the use of computer-based multimedia to improve the quality of undergraduate instruction in large undergraduate courses. Our project has created an image library of about 3500 computer graphics, animations, and digital video sequences for lecture support, as well as the software to present and manage this image library. During the past 3 years, students have used computers for modeling, simulation, and problem-solving activities in the laboratory of our evolution and ecology undergraduate course. Most recently, we have begun to integrate the World Wide Web into our curriculum in a variety of ways. This presentation demonstrates the comprehensive way in which our Program has combined these “new” information technologies into our introductory courses. The general applicability of this approach to any discipline will be discussed.
45
Klingelhöfer, Doris, Markus Braun, Dörthe Brüggmann, and David A. Groneberg. "The Pandemic Year 2020: World Map of Coronavirus Research." Journal of Medical Internet Research 23, no. 9 (September 8, 2021): e30692. http://dx.doi.org/10.2196/30692.
Full textAbstract:
Background SARS-CoV-2 is one of the most threatening pandemics in human history. As of the date of this analysis, it had claimed about 2 million lives worldwide, and the number is rising sharply. Governments, societies, and scientists are equally challenged under this burden. Objective This study aimed to map global coronavirus research in 2020 according to various influencing factors to highlight incentives or necessities for further research. Methods The application of established and advanced bibliometric methods combined with the visualization technique of density-equalizing mapping provided a global picture of incentives and efforts on coronavirus research in 2020. Countries’ funding patterns and their epidemiological and socioeconomic characteristics as well as their publication performance data were included. Results Research output exploded in 2020 with momentum, including citation and networking parameters. China and the United States were the countries with the highest publication performance. Globally, however, publication output correlated significantly with COVID-19 cases. Research funding has also increased immensely. Conclusions Nonetheless, the abrupt decline in publication efforts following previous coronavirus epidemics should demonstrate to global researchers that they should not lose interest even after containment, as the next epidemiological challenge is certain to come. Validated reporting worldwide and the inclusion of low-income countries are additionally important for a successful future research strategy.
46
Kerckhoven, Gilbert Van. "An Aboriginal Christmas Celebration." Australian Journal of Indigenous Education 27, no. 1 (July 1999): 28–34. http://dx.doi.org/10.1017/s1326011100001514.
Full textAbstract:
The Golden Hill Steiner School in Denmark, West Australia, is a small “alternative” school and part of the world wide Steiner/Waldorf school movement. In 1998 this young school had 56 students from kindergarten to class 6. Because of the small numbers, primary classes are combined (for 1998 this was a class 1/2, class 3/4 and class 5/6).
47
Johnson, Brian F. G., William P. Griffith, Robin J. H. Clark, John Evans, Brian H. Robinson, and Paul R. Raithby. "In memory of Lord Jack Lewis." Dalton Transactions 44, no. 9 (2015): 3896–903. http://dx.doi.org/10.1039/c4dt90196g.
Full textAbstract:
Jack Lewis was truly a Man for all Seasons. Prodigious energy combined with a deep understanding of his subject made Jack one of the true founding fathers of Modern Inorganic Chemistry. His contributions to a wide range of areas for over sixty years established him as one of the leading Chemists of his generation and this was recognised by awards from leading Scientific Societies throughout the World.
48
Mclean, Maxwell, Jason Roach, and Rachel Armitage. "Local variations in reporting deaths to the coroner in England and Wales: a postcode lottery?" Journal of Clinical Pathology 66, no. 11 (July 29, 2013): 933–36. http://dx.doi.org/10.1136/jclinpath-2013-201640.
Full textAbstract:
AimsIn England and Wales, doctors are charged with a responsibility either to report a death to the coroner or issue a medical certificate specifying cause of death. A lack of formal prescriptive or presumptive oversight has resulted in the promulgation by individual coroners of local reporting regimes. The study reported here identified overall and gendered variations in local reporting rates to coroners across the jurisdictions of England and Wales, consistent over time.MethodsAnalysis was performed on Ministry of Justice (MOJ) data pertaining to the numbers and proportions of deaths reported to the coroner by jurisdiction over a 10-year period (2001–2010). Office of National Statistics (ONS) data provided the numbers of deaths registered in England and Wales over the same period to serve as a denominator for the calculation of proportions. Where coroner jurisdictions (and local authorities) had been amalgamated during this period, the combined reported and registered death figures have been included in line with the current jurisdiction areas.ResultsWhile reporting rates for individual jurisdictions were found to be stable over the 10-year period, wide local variations in reporting deaths to coroners were found with no obvious demographic explanation. The gender of the deceased was identified as a major factor in local variation.ConclusionsThe decision to report a death to the coroner varies across jurisdictions. Implications for coronial investigations are discussed and the need for wider research into coroners’ decision-making is proposed.
49
Costa, Francisco Moscoso, Jorge Ferreira, Miguel Mendes, and João Carmo. "Dabigatran in real-world atrial fibrillation." Thrombosis and Haemostasis 116, no. 10 (2016): 754–63. http://dx.doi.org/10.1160/th16-03-0203.
Full textAbstract:
SummaryIn the RE-LY clinical trial, dabigatran presented a better effectiveness/ safety profile when compared to warfarin. However, clinical trials are not very representative of the real-world setting. We aimed to assess the performance of dabigatran in real-world patients with atrial fibrillation (AF) by means of a systematic review and meta-analysis of observational comparison studies with vitamin K antagonists (VKA). We searched PubMed, Embase and Scopus databases until November 2015 and selected studies according to the following criteria: observational study performed with nonvalvular AF patients; reporting adjusted hazard ratios (HR) of clinical events in a follow-up period; for dabigatran 75 mg, 110 mg or 150 mg versus VKA. Twenty studies were selected which included 711,298 patients, 210,279 of which were treated with dabigatran and the remaining 501,019 with VKA. Ischaemic stroke incidence was of 1.65 /100 patient-years for dabigatran and 2.85/100 patient-years for VKA (HR 0.86, 95 % confidence interval of 0.74–0.99). Major bleeding rate was 3.93/100 patient-years for dabigatran and 5.61/100 patient-years for VKA (0.79, 0.69–0.89). Risk of mortality (0.73, 0.61–0.87) and intracranial bleeding (0.45, 0.38–0.52) were significantly lower in patients treated with dabigatran when compared to patients on VKA. Risk of gastrointestinal (GI) bleeding was significantly higher in patients treated with dabigatran (1.13, 1.00–1.28). No significant difference was observed in risk of myocardial infarction (0.99, 0.89–1.11). In this combined analysis of real-world observational comparison studies with VKA, dabigatran was associated with a lower risk of ischaemic stroke, major bleeding, intracranial bleeding and mortality, higher risk of GI bleeding and a similar risk of myocardial infarction.Supplementary Material to this article is available online at www.thrombosis-online.com.
50
Daniel, Christel, and Dipak Kalra. "Clinical Research Informatics." Yearbook of Medical Informatics 29, no. 01 (August 2020): 203–7. http://dx.doi.org/10.1055/s-0040-1702007.
Full textAbstract:
Objectives: To summarize key contributions to current research in the field of Clinical Research Informatics (CRI) and to select best papers published in 2019. Method: A bibliographic search using a combination of MeSH descriptors and free-text terms on CRI was performed using PubMed, followed by a double-blind review in order to select a list of candidate best papers to be then peer-reviewed by external reviewers. After peer-review ranking, a consensus meeting between the two section editors and the editorial team was organized to finally conclude on the selected three best papers. Results: Among the 517 papers, published in 2019, returned by the search, that were in the scope of the various areas of CRI, the full review process selected three best papers. The first best paper describes the use of a homomorphic encryption technique to enable federated analysis of real-world data while complying more easily with data protection requirements. The authors of the second best paper demonstrate the evidence value of federated data networks reporting a large real world data study related to the first line treatment for hypertension. The third best paper reports the migration of the US Food and Drug Administration (FDA) adverse event reporting system database to the OMOP common data model. This work opens the combined analysis of both spontaneous reporting system and electronic health record (EHR) data for pharmacovigilance. Conclusions: The most significant research efforts in the CRI field are currently focusing on real world evidence generation and especially the reuse of EHR data. With the progress achieved this year in the areas of phenotyping, data integration, semantic interoperability, and data quality assessment, real world data is becoming more accessible and reusable. High quality data sets are key assets not only for large scale observational studies or for changing the way clinical trials are conducted but also for developing or evaluating artificial intelligence algorithms guiding clinical decision for more personalized care. And lastly, security and confidentiality, ethical and regulatory issues, and more generally speaking data governance are still active research areas this year.